# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN-TD
- Date: 1979-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Survivorship visit one year after diagnosis, after the yearly mammogram. **S**

## History of present illness

Ms. Lorde returns one year after her diagnosis. Her diagnostic mammogram of the left breast a week ago showed no suspicious findings (BI-RADS 1). She has taken tamoxifen daily for eleven months. Her hot flashes remain mild, one or two a day. Her periods are regular with no bleeding between them. She has no leg swelling, breathlessness, bone pain, cough, headaches, abdominal pain, or new lumps, and no arm swelling. She walks about 30 minutes most days. Her genetic counseling appointment is next week. **S**

| Element | Detail |
|---|---|
| Interval change | Left mammogram BI-RADS 1 a week ago |
| Tamoxifen | Eleven months, taken daily |
| Recurrence symptoms | None |
| Gynecologic | Regular periods; no intermenstrual bleeding |
| Genetic counseling | Next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; no night sweats |
| Endocrine | Positive | One or two mild hot flashes a day |
| Genitourinary | Negative | No abnormal vaginal bleeding |
| Cardiovascular | Negative | No leg swelling or chest pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

7 systems reviewed. **S**

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 71.8 kg; BMI 25.4 kg/m². All vital signs are synthetic.

PHQ-2: 0. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, no nodules or skin change; left breast without masses |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 29.0 cm on each side; calves soft and non-tender |
| Abdomen | Soft; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Stage IA right breast cancer one year after diagnosis, on adjuvant tamoxifen** (C50.411). No evidence of recurrence on history, examination, or mammogram. **S**
   - Written survivorship care plan given today: treatment summary, surveillance schedule, possible late effects of tamoxifen, and whom to call.
   - Continue tamoxifen 20 mg daily.
   - History and examination every three to six months to year three; next left mammogram in a year.
   - Yearly gynecologic assessment and flu vaccine at the preventive visit next month.
2. **Tamoxifen side effects: mild hot flashes** (Z79.810). Stable and tolerable. **S**
   - Continue non-drug measures.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No symptoms or signs of recurrence |
| Medication safety | Tamoxifen adherence and side effects | Every visit | Completed today | Taken daily for eleven months |
| Survey | Vasomotor symptom assessment | Periodically on endocrine therapy | Completed today | One or two mild hot flashes a day |
| Examination | Abnormal vaginal bleeding inquiry on tamoxifen | Every visit | Completed today | Regular periods; no intermenstrual bleeding; yearly gynecologic assessment booked for the preventive visit |
| Examination | Venous thromboembolism symptom inquiry on tamoxifen | Every visit | Completed today | No leg swelling, calf pain, or breathlessness |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Up to date | Done a week ago: BI-RADS 1; next in one year |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | No swelling; arm circumferences equal |
| Survey | Depression screen (PHQ-2) | At periodic intervals | Completed today | PHQ-2 score 0 |
| Survey | Fatigue, cognitive concerns, and sexual or vaginal symptoms | At each visit or periodically | Completed today | None reported |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended in asymptomatic stage I to III survivors | Not indicated | No symptoms to prompt testing; none ordered |
| Imaging | CT, bone scan, PET, or other imaging for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms; not ordered |
| Imaging | Bone density (DXA) | Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause | Not indicated | Premenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise |
| Referral | Genetic counseling | Once | Referred | Appointment next week |
| Self-management | Survivorship care plan | Within one year of completing primary treatment | Completed today | Written plan given and copied to medical oncology |
| Self-management | Healthy lifestyle counseling and second-cancer screening | Every visit | Completed today | Walking about 200 minutes a week; cervical and colorectal screening to be addressed at the preventive visit next month |

## Goal progress

- Continue tamoxifen daily with side effects she finds tolerable. Outcome by 1979-09-28: Taking it daily; mild hot flashes controlled without medicine; no abnormal bleeding or clot symptoms. **S**
- Complete the yearly surveillance mammogram of the left breast. Outcome by 1979-09-28: Left mammogram one year after diagnosis: BI-RADS 1. **S**
- Complete germline genetic assessment, missed at diagnosis. In progress; target 1979-10-19. **S**
- Keep at least 150 minutes of activity a week and a stable weight. Outcome by 1979-09-28: Walking about 200 minutes a week; weight stable at 71 to 72 kg. **S**

## Guideline basis

- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013), American Society of Clinical Oncology
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Genetic counseling next week. Adult preventive visit next month. Survivorship visit in January. **S**
- Next scheduled visit 1979-10-19: adult preventive visit. **S**
